|1.||Itami, Kenichiro: 1 article (08/2005)|
|2.||Yoshida, Jun-ichi: 1 article (08/2005)|
|3.||Muraoka, Nobuhiro: 1 article (08/2005)|
|4.||Mineno, Masahiro: 1 article (08/2005)|
|5.||Leonard, J: 1 article (06/2002)|
|6.||Alexander, R P: 1 article (06/2002)|
|7.||Higgs, G: 1 article (06/2002)|
|8.||Morphy, R: 1 article (06/2002)|
|9.||Gozzard, N: 1 article (06/2002)|
|10.||Zomaya, A: 1 article (06/2002)|
|2.||Asthma (Bronchial Asthma)
08/19/2005 - "A rapid synthesis of CDP840 (a potential therapeutic agent for asthma), using 2-pyrimidyl vinyl sulfide as a platform, has been established. "
07/01/1996 - "The novel series of tri-aryl ethanes, of which CDP840 is the lead compound, could be the basis of an orally active prophylactic treatment for human asthma."
02/01/1998 - "The activity of CDP-840, a novel, selective phosphodiesterase IV inhibitor was determined in a leukotriene-dependent non-human primate model of allergic asthma. "
|3.||Pulmonary Eosinophilia (Eosinophilic Pneumonia)
07/01/1996 - "3. Antigen-induced pulmonary eosinophilia in sensitized guinea-pigs was reduced dose-dependently by CDP840 (0.01-1 mg kg-1, i.p.) and intracellular EPO levels were significantly higher. "
07/01/1996 - "Antigen-induced pulmonary eosinophilia was reduced (93%) in budesonide and (85%) in CDP840 treated rabbits. "
06/03/2002 - "CDP840 is non-emetic in the ferret at 30mgkg(-1) (po), active in models of inflammation and reverses ozone-induced bronchial hyperreactivity in the guinea pig."
07/01/1996 - "1. The effects of the inhaled corticosteroid budesonide and a novel PDE 4 inhibitor CDP840 given systematically, were evaluated in a model of antigen-induced airway inflammation in the rabbit. "
07/01/1996 - "The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4."
07/01/1996 - "CDP840 is stereo-selective since its S enantiomer (CT 1731) is 10-50 times less active against all forms of PDE 4 tested while both enantiomers are inactive (IC50S: > 100 microM) against PDE types 1, 2, 3 and 5. 2. Oral administration of CDP840 caused a dose-dependent reduction of interleukin-5 (IL-5)-induced pleural eosinophilia in rats (ED50 = 0.03 mg kg-1). "
07/01/1996 - "CDP840 and budesonide also prevented antigen-induced AHR and eosinophilia in the immunised rabbit."
|4.||Phosphodiesterase 4 Inhibitors
|5.||Type 4 Cyclic Nucleotide Phosphodiesterases
|7.||Interleukin-5 (Interleukin 5)